DGAP-Adhoc: 4SC AG: Subgroup analysis suggests survival

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 5, 2016 at 4:45 AM

DGAP-Adhoc: 4SC AG: Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat

4SC AG / Key word(s): Study results 05.10.2016 10:32 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- 4SC AG: Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat Planegg-Martinsried, Germany, 5 October 2016 - 4SC AG (4SC, FSE Prime Standard: VSC) and its development partner Yakult Honsha Co., Ltd. (Yakult Honsha) retrospectively analyzed the data of the randomized, multicenter Phase II study, conducted by Yakult Honsha in Japan and South Korea. The study investigated the effect of 4SC's epigenetic cancer drug resminostat in combination with the standard of care drug sorafenib compared with sorafenib monotherapy as a potential novel first-line treatment for patients with advanced liver cancer (hepatocellular carcinoma, HCC). Treatment with resminostat in combination with sorafenib demonstrated a substantial overall survival (OS) benefit compared with sorafenib monotherapy in a large subgroup comprised of 84 patients (50 % of all patients in the study) with a greater than median platelet count at study entry. As overall survival (OS) is the most relevant clinical endpoint in advanced HCC, the findings of the subgroup analysis provide important knowledge for the future clinical development of resminostat in combination with sorafenib in this indication. Based on these results, 4SC and Yakult are currently discussing their plans for continued clinical development of resminostat. The results of the study will be published by Yakult Honsha and the investigators at an upcoming scientific conference. --------------------------------------------------------------------------- Information and Explanation of the Issuer to this News: About 4SC 4SC (www.4sc.com) is a biotech company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options for cancer patients that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 50 employees as of 30 June 2016. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005. Forward-looking information Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward- looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. 4SC Corporate Communications & Investor Relations Dr Anna Niedl, anna.niedl@4sc.com, +49 89 700763-66 Wolfgang Güssgen, wolfgang.guessgen@4sc.com, +49 89 700763-73 MC Services Katja Arnold, katja.arnold@mc-services.eu, +49 89 210228-40 The Ruth Group Carol Ruth, cruth@theruthgroup.com, +1 646 536 7004 05.10.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: 4SC AG Am Klopferspitz 19a 82152 Planegg-Martinsried Germany Phone: +49 (0)89 7007 63-0 Fax: +49 (0)89 7007 63-29 E-mail: public@4sc.com Internet: www.4sc.com ISIN: DE000A14KL72 WKN: A14KL7 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SeaWorld Rings in Holidays with All-New Festivities

Holiday Transformation at SeaWorld's Parks The holiday spirit isn't something you purchase—it’s an experience. And boy, SeaWorld seems to get this right. As the chill of late October settles in, SeaWorld parks across Orlando, San Diego, and San Antonio start dressing up for the holiday season, morphing into a spectacle of lights and festive joy. For anyone who’s...

JOIA Rose Hall Revives Jamaican Luxury Experience

A New Chapter for Jamaican Luxury If there's one thing that gets the blood pumping, it's a massive overhaul of a decades-old resort, especially one sitting pretty on Montego Bay's golden shores. December 1, 2026, marks the return of JOIA Rose Hall to the hospitality scene—shiny, revamped, and all about delivering an oasis fueled by authentic Jamaican culture. Forget...

LanguageLine AI App Earns Vizient Technology Kudos

Tech Talk: LanguageLine's AI App Gains Important Recognition Diving headfirst into the chaotic world of healthcare, LanguageLine's AI Translation App earned a standout accolade. Just announced, it's snagged the Innovative Technology Designation from Vizient, the heavyweight champ in healthcare performance improvement. On the scene since the end of October, they rolled the...

ACACIA's Big Move with Bel-Mac and Seashore: Will It Pay Off?

A New Powerhouse in Roofing Services? Take a seat, folks—we're talking about a regional shakeup in the world of roofing and exterior building. ACACIA Exterior Building Group, based out of Alexandria, Virginia, just tightened its grip on the Mid-Atlantic and Gulf Coast markets by investing in Bel-Mac Roofing and Seashore Construction. This ain't just your run-of-the-mill...

Thunderly Bags Davey Awards for Creative Franchise Videos

Big Wins from Humble Beginnings Ever notice how some small outfits have a knack for punching above their weight? Thunderly, a Dallas-based marketing agency, is a shining example of that. They've just snagged two Silver Awards at the 22nd Annual Davey Awards—and it’s stirring up talk across the sector. Winning a Davey isn’t child's play; it’s about small teams...

Bitcoin Mortgages: APX Ushers in New Canadian Era

Bitcoin Meets Canadian Mortgages: A Game Changer? Here's a scenario you didn't see coming: Bitcoin, the digital darling of the new millennium, now backing Canadian mortgages. If that doesn't get your financial senses tingling, maybe you haven't been paying attention. APX Lending, a pioneer in digital-asset-backed lending, is kicking open the doors to a fresh financial...

McKay Brothers Enhances Fastest Routes for Market Data

Breaking Down McKay Brothers' Latest Maneuver Yeah, the financial market isn't just numbers and screens—it's about moving those numbers faster than a cheetah chasing prey. McKay Brothers knows this game inside and out, and they're laying down new wires, or rather, wireless, to make sure they've got the quickest routes in the room. Let me tell you, they're throwing money...

Virax Biolabs Expands China Reach With Key Partnerships

Virax Biolabs' Strategic Play in China Does Virax Biolabs have a trick up its sleeve, or is it just rolling the dice in the vast Chinese market? With three new distributor agreements, it sure seems like it's trying to tip the scales in its favor. The London-based company announced new distribution agreements for its ImmuneSelect research-use immune profiling products....

Frontera Energy's Q3 Results Call: Key Insights Ahead

What to Expect from Frontera’s Upcoming Call Frontera Energy’s got a date with the earnings table, and it’s set for November 11. The story here is about anticipation, folks. This Canadian energy player will lay its third-quarter results bare soon as trading wraps up. They’ll be breaking the nitty-gritty down in a call with the analysts that follows the next day,...

FirstEnergy Bolsters Support for Shelter Initiatives

FirstEnergy Foundation's Commitment Shines Bright Alright, here's the scoop. FirstEnergy Foundation isn't just about keeping the lights on anymore. They're throwing down $620,000 to tackle one hell of a tough nut—shelter and stability. This latest infusion spreads across five states, with ten nonprofit warriors in New Jersey alone locking in $120,000 of that pot for...